中文
中文
为了病患而驱动的创新
Patient-first cell therapy innovation

2020
  • 0
Qin D., Li D., Zhang B., Chen Y., Liao X., Li X., Alexander P.B., Wang Y.,* Li Q.-J.* (2020) Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models. OncoImmunology 9(1):1806009. (*: Corresponding authors, PMCID: PMC7458607)

Zhang Y., Mudgal P., Wang L., Wu H., Huang N., Alexander P.B., Gao Z., Ji N. & Li Q.-J. (2020) T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma. OncoImmunology, 9(1):1749476. (PMCID: PMC7153824)
03.23
2022
来源:
关键词:
相关阅读

Copyright © 2019 天科雅生物医药科技有限公司

粤公网安备 44011502000528号

粤ICP备20056630号 Powered by vancheer
关于天科雅
研究与发展
产品及临床
新闻与媒体
招贤纳士

Copyright © 2019 天科雅生物医药科技有限公司

粤公网安备 44011502000528号

粤ICP备20056630号 Powered by vancheer